StemCell Therapy

Nov 29, 2019 (Thomson StreetEvents) -- Edited Transcript of Marker Therapeutics Inc earnings conference call or presentation Tuesday, November 12, 2019 at 10:00:00pm GMT

* Anthony H. Kim

Marker Therapeutics, Inc. - CFO

Marker Therapeutics, Inc. - SVP of Clinical Development

* Peter L. Hoang

Marker Therapeutics, Inc. - President, CEO & Director

Roth Capital Partners, LLC, Research Division - MD, Senior Equity Analyst & Head of Biotechnology Research

Nomura Securities Co. Ltd., Research Division - Research Analyst

Oppenheimer & Co. Inc., Research Division - Associate

Janney Montgomery Scott LLC, Research Division - Equity Research Analyst & Director of Biotechnology Research

Greetings, and welcome to the Marker Therapeutics Third Quarter 2019 Operating and Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to our host, Tony Kim, Chief Financial Officer. Thank you. You may begin.

Anthony H. Kim, Marker Therapeutics, Inc. - CFO [2]

Thank you, and welcome, everyone, to our third quarter 2019 earnings call. The press release reporting our financial results is available in the News section of our corporate website at markertherapeutics.com. Joining me for the call today are Peter Hoang, our President and Chief Executive Officer; Dr. Juan Vera, Chief Development Officer; and Dr. Mythili Koneru, Senior Vice President of Clinical Development.

As a reminder, we will be making forward-looking statements during today's call. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q on file with the SEC.

I would now like to turn the call over to Peter Hoang.

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [3]

Thank you, Tony. Good afternoon, everyone, and thanks for joining us.

We continue to make progress advancing our MultiTAA T cell therapies across various hematologic and solid tumor cancers in the quarter. In ongoing partner-sponsored clinical studies with MultiTAA T cells at Baylor College of Medicine, patients are experiencing durable responses, some over 5 years, with virtually no meaningful treatment-related toxicities. And while it's early days, we are encouraged by the promising results delivered by our novel T-cell immunotherapy particularly in such challenging disease areas.

In anticipation and support of future Marker-sponsored clinical trials, we continue to build out our infrastructure and expand our team. We anticipate the next 12 to 18 months to be an exciting and productive time for our company.

As you may recall, based on the breadth of data collected across the Baylor-sponsored studies, we have selected acute myeloid leukemia, or AML, as our lead indication for our first company-sponsored clinical trial. We recently filed a new Investigational New Drug application, or IND, with the U.S. FDA as part of a planned Marker Phase II study in post-allogeneic hematopoietic stem cell transplant patients with AML in both the adjuvant and active disease settings. Upon reviewing our submission, the FDA requested additional information regarding certain quality and technical specifications for 2 reagents supplied by third-party vendors that are used in our manufacturing process. These reagents are ancillary products used in manufacturing and are not present in the final product. However, because the data are needed to clear the IND, the trial has been placed on hold until our complete response to the technical questions is deemed satisfactory to the FDA.

Because the agency's questions were directed to third-party products rather than our own process or product, we worked with the regulatory and quality groups at the respective manufacturers to address the FDA's request. After receiving the required information from them, we submitted our complete response to the agency in late October, and regulators have 30 days to respond. We will communicate an update and our plans to move forward once these questions have been addressed. Given the various resolution scenarios, we are confident that we can initiate the trial in 2020 and hope to provide more precise time lines later this year.

We recognize the need for new, improved therapies in AML. And advancing our novel T-cell candidate, which we believe can have a significant impact on the treatment of this patient population, remains our top priority. In fact, AML is the most common acute leukemia in adults and progresses rapidly without treatment. The prognosis for these patients is poor with a 5-year survival rate of 28% and a high risk of relapse necessitating the need for improved treatments. Current options are mostly limited to chemotherapy, sometimes in combination with a bone marrow transplant. Both treatments carry a risk of bleeding, life-threatening infections and permanent infertility. Bone marrow transplants also carry risk of graft-versus-host disease, also known as GVHD.

We believe that our MultiTAA therapy may have several advantages over standard approaches as well as other T cell therapies in development. In contrast to monospecific T cells, MultiTAA T cells recognize up to 5 antigens and allow for epitope spreading, leading to a more potent, durable antitumor response. And unlike transplants that require hospital stays, MultiTAA is administered in an outpatient setting.

MultiTAA-based cell therapy is our central focus, but we are also advancing several legacy vaccine-based programs. To date, clinical results in our breast cancer trials have showed continuing progress, including, based on a preliminary analysis of 34 patients enrolled in a triple-negative breast cancer trial to date, 31 have showed meaningful immune responses to vaccine treatment. Of 80 patients treated at 11 clinical sites, 14 have shown disease progression as of September 30, 2019, following treatment with TPIV200.

We have, however, made the decision to discontinue the development of our cancer vaccine in patients with platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results from our Phase II study conducted by an independent Data and Safety Monitoring Board, or DSMB. Although the DSMB did not express any safety concerns with respect to TPIV200, we have elected to suspend the trial as it did not meet our threshold for probability of success based upon our prespecified criteria. Pending full review of the data, we anticipate closing the trial in the first quarter of 2020.

Unlike the ovarian cancer trial, there is no formal interim analysis in the breast cancer trial. The last patient will complete the trial in Q2 2021, at which time we will communicate the results and make a decision on next steps for that product.

With that, I will turn the call over to Tony to review financials. After that, we look forward to taking your questions.

--------------------------------------------------------------------------------

Anthony H. Kim, Marker Therapeutics, Inc. - CFO [4]

--------------------------------------------------------------------------------

Thanks, Peter. Net loss for the quarter ended September 30, 2019, was $5.5 million compared to a net loss of $4.4 million for the quarter ended September 30, 2018.

Research and development costs during the 3 months ended September 30, 2019, was $3.1 million compared to $1.9 million during the 3 months ended September 30, 2018. The increase of $1.2 million was primarily attributable to increases in personnel-related expenses relating to the buildup of our internal infrastructure.

General and administrative expenses were $2.5 million during the 3 months ended September 30, 2019, as compared to $2.6 million during the 3 months ended September 30, 2018. The decrease was primarily attributable to $0.6 million of merger-related expenses incurred during the 3 months ended September 30, 2018, offset by increased expenses in head count-related legal and other professional expenses.

I will now turn the presentation back over to Peter for final remarks.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

Thanks, Tony. I'll open the call for questions. Operator?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from Christopher Marai with Nomura Instinet.

--------------------------------------------------------------------------------

Jackson Dean Harvey, Nomura Securities Co. Ltd., Research Division - Research Analyst [2]

--------------------------------------------------------------------------------

This is Jackson Harvey on for Christopher Marai. I'm just curious, after the FDA resolves the clinical hold with the response to their technical concerns, how quickly will you be able to start dosing patients?

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [3]

--------------------------------------------------------------------------------

Thanks for the question. That's a great question. We've not stood still in the meantime. In fact, I think that preparations for initiation of the trial are fully underway. In fact, we're progressing ahead of plan in the site enrollment plan. To date, we have visited over 20 sites who are now waiting for an accepted IND number. Once we have an accepted IND number, we can get the IRB and contracting process started with those sites. And so I do anticipate that we should be able to start the trial promptly after acceptance of the IND.

--------------------------------------------------------------------------------

Operator [4]

--------------------------------------------------------------------------------

Our next question comes from Ted Tenthoff with Piper Jaffray.

--------------------------------------------------------------------------------

Edward Andrew Tenthoff, Piper Jaffray Companies, Research Division - MD & Senior Research Analyst [5]

--------------------------------------------------------------------------------

Just following up on that, what are some of the outstanding issues with respect to the IND hold? And just to be a little bit clearer on timing, what are the next steps exactly? I want to make sure I understand that.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [6]

--------------------------------------------------------------------------------

Yes, absolutely, Ted. Why don't I turn the question over to Mythili Koneru, our Head of Medical Operations?

--------------------------------------------------------------------------------

Mythili Koneru, Marker Therapeutics, Inc. - SVP of Clinical Development [7]

--------------------------------------------------------------------------------

Regarding -- thank you, Peter. To address your -- the first part of your question, the FDA requested additional information specifically regarding certain quality and technical specifications for 2 reagents that were supplied by a third-party vendor that we use in our manufacturing process, but it's actually not present in the final product infused to patients. So because the FDA requires these data before planning -- allowing any of these planned studies to move forward under this IND, the IND was placed on clinical hold until our complete response to the technical questions is satisfactory to FDA.

So the idea that as we communicated in the press release, we've been working with the regulatory and quality groups at these respective manufacturers to address the FDA's request. And we've submitted a complete response to these issues that was raised by the FDA on October 28, 2019. So the FDA is going to respond within 30 days after receiving the complete responses and then indicate whether the hold is actually lifted. And if not, specifically the reasons why the clinical trial...

--------------------------------------------------------------------------------

Edward Andrew Tenthoff, Piper Jaffray Companies, Research Division - MD & Senior Research Analyst [8]

--------------------------------------------------------------------------------

That's really, really helpful because I think it puts into perspective just how maybe, hopefully, minor that says for the IND. So all the best in getting that up and going, and we're excited to hear more about the studies.

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [9]

--------------------------------------------------------------------------------

Thanks, Ted. We really do see it as sort of not atypical from what we're seeing across the industry in biologics right now -- in cell therapy. So appreciate it.

--------------------------------------------------------------------------------

Operator [10]

--------------------------------------------------------------------------------

Our next question comes from Matt Biegler with Oppenheimer & Company.

--------------------------------------------------------------------------------

Matthew Cornell Biegler, Oppenheimer & Co. Inc., Research Division - Associate [11]

--------------------------------------------------------------------------------

Peter, what do you think really could be a worst-case scenario here with this IND delay? Do you think the FDA might require you to find a new vendor for those reagents that you mentioned? And if so, I mean how long would you estimate it would take to do equivalence testing?

--------------------------------------------------------------------------------

Peter L. Hoang, Marker Therapeutics, Inc. - President, CEO & Director [12]

--------------------------------------------------------------------------------

Yes. Matt, that's a good question. Let me once again refer to Mythili here. From what I can say, I think that the FDA acceptance at this point is really the gating item for us to start. Like I said, the site enrollment has gone, if anything, better than expected. And so I do think that we should be able to get pretty fast start as soon as we get acceptance.

My, do you have anything further to add?

--------------------------------------------------------------------------------

Mythili Koneru, Marker Therapeutics, Inc. - SVP of Clinical Development [13]

--------------------------------------------------------------------------------

Yes. I just would like to reiterate that we have been working very closely with these respective manufacturers and have submitted the response to the FDA's question. We do expect to initiate the Phase II clinical trial of our MultiTAA program for the treatment of post-transplant AML in 2020, and we feel confident about that.

--------------------------------------------------------------------------------

Matthew Cornell Biegler, Oppenheimer & Co. Inc., Research Division - Associate [14]

--------------------------------------------------------------------------------

Okay. That's helpful. And so the agency didn't have any concerns with the actual design of the AML trial, and you're still planning on moving forward with that same design, looking at both relapsed/refractory as well as maintenance patients, is that correct?

--------------------------------------------------------------------------------

The rest is here:
Edited Transcript of MRKR.OQ earnings conference call or presentation 12-Nov-19 10:00pm GMT - Yahoo Finance

Crystal market research acknowledges the inclusion of a second report to a Global Biotechnology Market. The report summarizes the players that are perceptible in the Biotechnology market with an exact objective to provide a rationalist and purpose of their unpretentious forces of this current Biotechnology market, as the provincial and product segments are likewise expected at length, bearing in mind the Biotechnology objective to grant a granular example of this economys collapse.

The Biotechnology report expands coverage of business and market trends that are chief. The Biotechnology industry research incorporates require, predictions and classical market data, application information and cost trends, and business stocks. The Biotechnology analysis divides the sector dimensions, by price and volume, dependent on geography and application type.

Get the FREE PDF of this Research Report Now! @https://www.crystalmarketresearch.com/report-sample/HC012294

Continued

Inquiry More about this Research Report Now!: https://www.crystalmarketresearch.com/send-an-enquiry/HC012294

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC012294

Contacts Us:

Sherry | APAC Marketing Division: Level 23-1, Premier Suite

Mont Kiara, 50480 Kuala Lumpur

Malaysia

E-mail: sales@crystalmarketresearch.com

Read more from the original source:
New innovative report on Biotechnology Market to Boom In Near Future by Industry Key Players: Merck & Co,Abbott Laboratories,Novo Nordisk - Day...

Shutterstock

China is rapidly gaining on the United States when it comes to creating technology that mitigates disease threats and developing pharmaceuticals faster, and its a phenomenon driven by a philosophy that the state, military, and the private sector are one in the same.

That was the testimony of Tara J. OToole, senior fellow and executive vice president at In-Q-Tel, before the U.S. Senate Armed Services Subcommittee on Emerging Threats and Capabilities. The hearing, Biological Threats to U.S. National Security, examined everything from Chinas push to develop biotechnology infrastructure to luring research scientists away from the United States to work in China.

China has said repeatedly and forcefully, and theyre backing up their words with actions, that they intend to own the biorevolution, OToole said. And they are building the infrastructure, the talent pipeline, the regulatory system, and the financial system they need to do that.

China is partly accomplishing this by combining its internet giants, such as Alibaba, with its biotech companies. The combined strength of these companies research focuses on the industrialization of artificial intelligence in which China is institutionalizing it whereas the United States is only experimenting with it, OToole added.

Chinas goal is to make biotechnology 5 percent of the countrys GDP by 2020. China has changed regulations for its own version of the Food and Drug Administration to be more like that of the United States in order to more easily market to the world. The country has created a talent pipeline that incentivizes its own students to go into the life sciences and bioengineering. China also has at least 20 programs intended to bring scientific talent from the rest of the world.

There are good reasons China is going after the biorevolution: it has the highest incidences of cancer on earth and the population is aging. It also must find an affordable way to deliver health care to a rising middle class.

And China is delivering health care to the world. The country is the largest producer of active pharmaceutical ingredients. However, reliance on foreign pharmaceuticals has national security implications. As many as 80 to 100 percent of critical drugs are manufactured outside the United States. U.S Sen. Gary Peters (D-MI) told the committee that following the 2001 anthrax attacks, the U.S. was dependent on a single foreign source for a broad-spectrum antibiotic to treat anthrax.

To what extent is the U.S. reliant on foreign sources for key drug products and medical supplies such as syringes and needles and other critical medical supplies that we would need to respond to a biological attack today? Peters asked the panel of experts.

The United States is critically dependent on China for several drugs and has been shipping manufacturing capacity to Asia for more than a decade.

There isnt a CEO of a major pharma company that hasnt been recruited by China to build facilities there, OToole said.

To address the drug supply chain, the United States has begun exploring the possibility of using synthetic biology to make active pharmaceutical ingredients, especially in response to epidemics.

If there were a natural pandemic in which the entire world needed drugs, Im sure China, as we would, take care of its own people first. Yet, we dont have the surge capacity to produce enough very common, well-used medicine in time to deal with an epidemic, OToole said.

Thomas Inglesby, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, told the committee that the U.S. treats medicines too much like commodities that can be sourced for the lowest price somewhere in the world.

In a crisis, everyone in every part of the world would be looking for medicine at the same time, Inglesby said. There should be at least a strategic examination of the kinds of things we must have, and we should consider how to bring some of those medicines back to the U.S. Obviously that cant be done with all medicines. Were an interconnected world. But for national health crises, we should be thinking about making them here.

Part of the problem is that the United States has not done a good job at translating biology to products, OToole said, or building infrastructure for securing and promoting the bioeconomy. Our translational infrastructure for biology is mostly coming from small start-up companies in the private sector, which are the innovation engines for biology, but do not provide the robust infrastructure to manage epidemics, whether deliberate or natural.

The experts made the following recommendations:

* Take on synthetic biology as a national security priority;* Use the National Defense Education Act to improve access to stem education and establish greater scientific careers within the U.S. government;* The contingency fund levels for the Centers for Disease Control and Prevention and USAID should be increased and sustained;* Support and strengthen the militarys infectious disease research laboratories;* Provide strong, coherent leadership at the National Security Council essential for guaranteeing effective oversight, long before a crisis emerges;* The U.S. Department of Agriculture should prioritize stronger crop surveillance, animal wildlife surveillance, more support for animal vaccine development, and more funding for agricultural biodefense overall;* Strongly support the biological weapons convention.

During epidemics, the U.S. should be able to immediately create diagnostics that could be used similarly to a pregnancy test so that people can determine for themselves who is sick and who isnt. Officials should be able to rapidly develop a new vaccine in response to an epidemic, OToole added.

These same tools also apply to diseases that affect agriculture and the U.S. animal supply. More than half of all infections that people contract are spread by animals.

Ill start by acknowledging that mother nature is a really good terrorist, Julie L. Gerberding, co-chair of the Commission on Strengthening Americas Health Security at the Center for Strategic and International Studies, told the committee. China today is experiencing a dreadful outbreak of swine fever that has probably cost the death or culling of at least 50 percent of their entire population of pork which is a major source of protein for people in China. So, this is a major socioeconomic threat to the state of China today and thats mother nature.

Swine fever, however, is not spread to humans, though it has a devastating economic impact. And U.S. farmers are concerned about trade and travel bringing such infectious diseases to this country.

I would say that the first alarming statistic is that we spend probably about 100 times less on agricultural threats than we do on human threats, Inglesby said. I think there are many reasons for this. But one includes a kind of reluctance within the U.S. government to talk about this threat until quite recently.

Continue reading here:
Chinese biotechnology dominates US Senate hearing on biological threats - Homeland Preparedness News

On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company thats ready to make a major impact in the agricultural sector.

May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 Presidents Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.

Strellas biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully hacked the fruit to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.

Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. Its a job that Shukurova says involves a lot of multitasking and requires an all-hands approach to problem solving.

We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans, says Shukurova about their companys work flow.

The company is also finding ways to expand their technology onto individual pallets in retail settings, which represents a huge untapped market for managing food waste. That opportunity, from a numbers perspective, is far greater than the current packing market were working in, so were hoping to make an impact as we move into that space as well, says Sizov.

During the next six months, the team will be busy analyzing the data collected by their deployed sensors and gearing up for a new round of fundraising. Looking further ahead, Strella aims to increase sales in their initial market, conduct research and development on individual pallet-level sensors, and begin active partnerships with larger retailers to help optimize their supply chains.

Sizov admits that Strella has an ambitious timeline but that the team is looking forward to the challenge. Working alongside Jordan, Liu, and Shukurova, Sizov says that Strella already has its own culture of sorts. None of us have ever had a business before, and learning how to create culture within a group, how to work together as a team, and how to not get tired of each other because we spend so much time together, has been an interesting challenge, says Sizov.

Their lab and coworking space at Pennovation has allowed Strella to stay connected with Penns innovator community while also providing lab facilities and resources needed to continue their work on their sensors. Strella has two lab benches and a fume hood, access to shared lab equipment, and plenty of space to house their prototypes, all provided for free as part of their Innovation Prize.

Theyve also been able to stay well-connected to the Penn community as a whole, traveling regularly to campus to meet with faculty, including weekly meetings with their mentorJeffrey Babin. We are not out of [the] Penn mindset, says Shukurova. We dont have to worry about exams, but were still on campus and were still involved with the faculty.

Babin says that Strella is one of the most exciting companies that Ive seen come out of Penn and that the company is in a strong position to make some significant impact on the food supply chain. One of the things thats been strong since the beginning was having an expanded vision: Not just on product development, but getting a customer, he says. They have a really strong sense of whats required to acquire a customer, what the next steps are, and growing both within the initial customer base while expanding to other elements.

When asked what advice they would give to would-be entrepreneurs, Shukurovas advice is to take it as a journey. She encourages students who have an idea to share their thoughts with others to get feedback before beginning any startup endeavor. Talk to more peopledont limit yourself to 10 people, or 20 people, talk to hundreds of people, she says.

Sizov says that the experience of running a startup has been a great learning experience, one that is far less risky than might seem at first, especially thanks to the Innovation Prize. If youre just following your passion, thats not a risk. Youre not putting aside your career, she says. Everything we learn at Strella is directly teaching us how to be better and smarter individuals.

Jeffrey Babin is a practice professor and associate director of the Engineering Entrepreneurship Program in the School of Engineering and Applied Science.

Homepage photo: Presidents Innovation Prize winners Katherine Sizov and Malika Shukurova (front) doing R & D to help design new versions of their fruit-hackingbiosensors at the Pennovation center.

Original post:
Strella Biotechnology tackles food waste by 'hacking the fruit' - Penn: Office of University Communications

Aravive Inc (ARAV) is near the top in its industry group according to InvestorsObserver. ARAV gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Aravive Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 87 out of 148 industries.

Click Here to get the full Stock Score Report on Aravive Inc (ARAV) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aravive Inc (ARAV) stock has fallen -15.53% while the S&P 500 has gained 0.17% as of 10:44 AM on Wednesday, Nov 27. ARAV is lower by -$1.46 from the previous closing price of $9.40 on volume of 1,348,672 shares. Over the past year the S&P 500 has risen 17.28% while ARAV has gained 43.06%. ARAV lost -$6.00 per share the over the last 12 months.

To screen for more stocks like ARAV click here.

View post:
Where Does ARAV Stock Rank in the Biotechnology Industry? - InvestorsObserver

I had one of those way-cool moments and what I now call the most memorable experience of my life this past week in Mombasa, Kenya.

It all started in late October, when I received an invitation from the African Agricultural Technology Foundation (AATF) to attend the Open Forum on Agricultural Biotechnology in Africa (OFAB) 2019 Media Awards on Nov. 21.

The AATF is a nonprofit organization focused on providing smallholder farmers in sub-Saharan Africa with practical technology solutions capable of addressing their farm productivity constraints and improving their livelihoods. One of its initiatives is OFAB, which works to enhance knowledge-sharing and awareness on agricultural biotechnology across seven African countries: Kenya, Tanzania, Ghana, Ethiopia, Uganda, Nigeria and Burkina Faso.

Exactly 18 days after receiving AATFs invitation, OFAB-Nigeria named me best agricultural biotechnology reporter in the print and online category and overall journalist of the year for my entry GMO debate affects public sentiment in Nigeria. I understood then that AATFs email was but a confirmation that I would be representing Nigeria at the continental level of the media awards in Mombasa.

As is typical of Mombasas fluctuating tropical climate, it was a relatively cool evening when the crme de la crmeof Africas science journalists joined scientists and policymakers from the seven OFAB countries for the media awards ceremony at the Sarova Whitesands Hotel. Dressed in a light-blue striped, knee-level kaftan, a black cap and a green-white-green traditional scarf, I joined the throng of people dressed primarily in their own colorful national and traditional garb.

Eugenia Abu, a veteran multimedia journalist who spoke on behalf of the panel of judges, said the awards were intended to acknowledge excellence in science journalism. We congratulate all the winners and urge for more synergy between science and journalism to enable AATF and OFAB to promote better lives for small-holder farmers on the continent through technology, Abu said.

As the crowd cheered, I heard my name announced as the winner in the print and online category. Visibly excited, but also bewildered, I began making my way to the stage. Many thoughts raced through my head at that auspicious moment, such as why are farmers in Africa slow in adopting agricultural innovations? I recalled that in developing my award-winning piece, I had interviewed many people on the streets who did not know what genetically modified organisms (GMOs) are or understand the term biotechnology.

Moreover, I thought again, studies have shown that our current trajectory for crop yields is insufficient to nourish the worlds population by 2050. Hence, with the worlds growing population and climate change, theres a need for greater and more consistent food production around the globe. This is particularly true in Africa, which is projected to hit 2.2. billion people by 2050.

Africa cannot achieve food sufficiency or realize its dream of becoming the food basket of the world without farmers having access to improved seeds, agricultural tools and technology on their farms. Thus journalists have a critical role to play in informing and educating African farmers and consumers about advances in modern agriculture and ensuring that farmers have access to options, including biotechnology. My aim is to connect these scientific innovations and technology to farmers in Africa through better communication.

On Nov. 23, as my Ethiopian Airlines return flight touched down in Abuja, I was filled with a sense of satisfaction for all that had transpired in Mombasa as well as nostalgia for the incredibly talented African journalists with whom I had shared the homey hospitality of the Sarova Whitesands Hotel for the past three days.

As a science journalist, I also felt a strong reconfirmation of my belief that Africas agriculture needs science and technology more than any other continent in the world. Consequently, African journalists must understand and believe in the potential of science and technology so as to report, write and communicate science accurately and spur economic development on the continent.

Asante!

Abdullahi Tsanni is a Nigerian science writer and Alliance for Science contributor.

Read the rest here:
Using media to connect African farmers with scientific innovation and technology - Alliance for Science

Robert W. Baird began coverage on shares of Vir Biotechnology (NYSE:VIR) in a report released on Wednesday, November 13th, The Fly reports. The firm issued a neutral rating on the stock.

Other analysts have also issued reports about the company. Cowen assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an outperform rating on the stock. Goldman Sachs Group began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Barclays began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has an average rating of Buy and an average target price of $29.00.

VIR stock traded up $0.07 during trading hours on Wednesday, hitting $11.90. 101,085 shares of the stock were exchanged, compared to its average volume of 164,664. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, November 19th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million during the quarter.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of the companys stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Vir Biotechnology (NYSE:VIR) Coverage Initiated by Analysts at Robert W. Baird - TechNewsObserver

Global Biotechnology Marketis expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Biotechnology Market : North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On...

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Companys novel T-cell activating immunotherapy platform, Versamune, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Details for the presentation are below:

Presentation Title: Versamune: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST

The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways. Versamunes mechanism of action involves the effective cross-presentation of tumor antigens via the MHC Class I and Class II pathways to prime tumor-specific CD8+ and CD4+ T-cells as well the potent up-regulation of Type 1 interferon genes within the lymph nodes, promoting effective T-cell migration, activation and proliferation. These mechanisms promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ killer T-cells. Versamunes activation specifically of type 1 interferons coupled with the lack of significant systemic cytokine release results in a highly favorable safety profile that has potential uses in combination with checkpoint inhibitors and other therapeutic agents. In a phase 1 human clinical trial PDS Biotechnologys lead Versamune-based immunotherapy exhibited potent antigen-specific CD8+ T-cell induction with an average of over 20-fold increase in the blood circulation within 14 days of treatment. The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients. The ability to induce high levels of CD8+ killer T-cells in vivo has resulted in potent synergy with checkpoint inhibitors in preclinical studies. Upcoming phase 2 clinical trials to confirm the unique synergy will also be presented.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Read this article:
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 - Yahoo Finance

REPORTING FOR 2019-11-28 | WCX19.ORG: We have done an in-depth analysis of how PDSB has been trading over the last 2 weeks and the past day especially. On its latest session, PDS Biotechnology Corporation (NASDAQ:PDSB) opened at 2.22, reaching a high of 2.38 and a low of 2.1007 before closing at a price of 2.27. There was a total volume of 37786.

VOLUME INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We saw an accumulation-distribution index of 7.27226, an on-balance volume of -2.08, chaikin money flow of 2.49125 and a force index of 1e-05. There was an ease of movement rating of 0.0024, a volume-price trend of -1.16026 and a negative volume index of 1000.0.

VOLATILITY INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We noted an average true range of 0.2508, bolinger bands of 2.11962, an upper bollinger band of 2.06108, lower bollinger band of 2.1007, a bollinger high band indicator of 1.0, bollinger low band indicator of 1.0, a central keltner channel of 2.23357, high band keltner channel of 2.07357, low band keltner channel of 2.39357, a high band keltner channel indicator of 1.0 and a low band keltner channel indicator of 1.0. There was a donchian channel high band of 2.1007, a donchian channel low band of 2.1007, a donchian channel high band indicator of 1.0, and a donchian channel low band indicator of 1.0.

TREND INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We calculated a Moving Average Convergence Divergence (MACD) of -0.00046, a MACD signal of -0.00026, a MACD difference of -0.00021, a fast Exponential Moving Average (EMA) indicator of 2.1007, a slow Exponential Moving Average (EMA) indicator of 2.1007, an Average Directional Movement Index (ADX) of unknown, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 1.0, a negative VI of 1.0, a trend vortex difference of 0.09678, a trix of -42.69843, a Mass Index (MI) of 1.0, a Commodity Channel Index (CCI) of -66.66667, a Detrended Price Oscillator (DPO) of 2.36666, a KST Oscillator (KST) of -529.76734 and a KST Oscillator (KST Signal) of -529.76734 (leaving a KST difference of -1.1584). We also found an Ichimoku rating of 2.3, an Ichimoku B rating of 2.3, a Ichimoku visual trend A of 4.40959, an Ichimoku visual trend B of 3.78933, an Aroon Indicator (AI) up of 4.0 and an AI indicator down of 4.0. That left a difference of -4.0.

MOMENTUM INDICATORS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): We found a Relative Strength Index (RSI) of 50.0, a Money Flow Index (MFI) of 34.08787, a True Strength Index (TSI) of -100.0, an ultimate oscillator of -13.38052, a stochastic oscillator of 174.5625, a stochastic oscillator signal of 174.5625, a Williams %R rating of 74.5625 and an awesome oscillator of -0.00285.

RETURNS FOR PDS BIOTECHNOLOGY CORPORATION (NASDAQ:PDSB): There was a daily return of -52.97673, a daily log return of -0.99027 and a cumulative return of -0.98539.

What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and thats OK (though we do advise learning these things). The bottom line is that AS OF 2019-11-28 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for PDS Biotechnology Corporation (NASDAQ:PDSB)

DISCLAIMER: We are not registered investment advisers and the above analysis should be taken at face value only. We strongly advise against buying or selling PDS Biotechnology Corporation (NASDAQ:PDSB) based solely on our analysis above, and are not responsible for any losses that you may incur if you choose make any investment decisions based on the above.

The rest is here:
PDS Biotechnology Corporation (NASDAQ:PDSB): The Good, The Bad, The Ugly (2019-11-28) - WCX19

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/genome-editing-services-world-markets-to-2030-focus-on-crispr---the-most-popular-genome-manipulation-technology-tool-300966100.html

SOURCE Research and Markets

Excerpt from:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community

Appiah rang Leukaemia Cares helpline from the point of diagnosis until well after the end of her daughters life. Sometimes Id call them as a means of support, she says, when things got really rough, when her medications were really powerful, and the chemo made her so unwell. She rang when she had panic attacks; an NHS psychologist had told her that these were likely, and that she should breathe into a brown paper bag, but Appiah found speaking to a person more soothing.

With a laugh, Appiah notes that shed ring the helpline at other times, too: Sometimes Id be out with Imogin, and shed be in the pram, being naughty, and all of my patience was going down the drain, and Id phone Leukaemia Cares nurses, and say: Look, Im feeling so depressed, my daughters shouting, I dont know what to do!

But I might also say: Nurse, Im actually feeling good today.

Appiah says the support of an independent person was invaluable: When your child is so ill, you need to speak to someone who doesnt know your name you need an outsider you can unload to. I didnt want anyone thinking: Here Sheila comes again!

You become self-conscious about your situation and dont want to be a burden on your friends and family. With the helpline, you wont be judged: they just listen. You get it out of your system and then go do the shopping at Sainsburys.

When Imogin was well, shed go to school. But she also spent weeks at a time in isolation in St Georges Hospital, with her mother by her side. Once, she had a bad reaction to a medication and went into cardiac arrest. She was crying and saying, Please, please! and they were giving her all sorts of medicine. The doctors were battling to keep her stable and I dived into the bed with her and told her: Youre going to be OK. I lay down with her and I started singing with her. And then, once she stabilised, she said: Now can I watch High School Musical?"

Appiah shakes her head, laughing: Thats what she was like: I was on thedoor of death, but I have something else planned. I want to watch my video and none of you are going to stop me!

Charities sent the pair to Disneyland Paris twice. The first time was fantastic, says Appiah, the second time Imogin was in and out of consciousness. But they said we should go, to make memories, Appiah explains. Imogin got to be a celebrity for a day and went to Hamleys in a limousine to get anything she wanted.

See the original post:
'My daughter's death took me to the darkest place, but I've learned it's possible to come back' - Telegraph.co.uk

GammaDelta Therapeutics is a company that focusses on utilizing the unique properties of gamma delta () T cells to develop novel immunotherapies for patients.Through their research, the companys scientists have discovered a number of targets and antibodies that have the potential to modulate the activity of T-cells in situ. Therefore, GammaDelta Therapeutics recently announced the formation of Adaptate Biotherapeutics, a spin-out company that will focus on research in this area.

Technology Networks spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Molly Campbell (MC) Please can you tell us more about T-cell based cell therapy products and their potential applications?Natalie Mount (NM): T cells play an increasingly appreciated critical role in immune surveillance, being able to recognize malignant/transformed cells through a pattern of stress markers. The recognition mechanism is not major histocompatibility complex (MHC) restricted and not dependent on a single antigen.

T cells therefore have potential in a range of disease indications, including both hematological and solid malignancies and a positive correlation between T cell infiltration and prognosis/survival in patients has been determined in a range of oncology indications in studies published in the literature by other groups. Additionally, as a cell therapy, T cells can be used in an allogeneic setting (ie, T cells can be used for unrelated recipients without a requirement for matching).

Both Adaptate Biotherapeutics and GammaDelta Therapeutics are focussed on harnessing the potential of T cells, in particular the V1 subtype which is the predominant T cell type in tissue.This is based on data originating from the labs of Professor Adrian Hayday of Kings College London and the Crick Institute, supported by Cancer Research Technology and also from Professor Bruno Silva Santos of Institute for Molecular Medicine at the University of Lisbon, Portugal.

Previous clinical trials conducted by other groups/companies targeting or using T cells in cancer have focussed on the V2 subtype which is predominant in the blood. These trials have demonstrated safety, but efficacy has been limited.Compared to V2 cells, V1 cells, which are the focus of work at Adaptate Biotherapeutics and GammaDelta Therapeutics, are less susceptible to exhaustion and activation induced cell death. Expansion of donor derived V1 has been shown to be a positive prognostic indicator for acute myeloid leukemia patients following hematopoietic stem cell transplant.

MC: Why are current immunotherapy treatment approaches limited?NM: Immunotherapy approaches have had very significant success and impact in Oncology recently, however, challenges and unmet needs remain.One challenge is effective treatment of solid tumors. The hypoxic, low nutrient tumor environment provides a challenge for successful infiltration and activation of T cells. However, V1 T cells have real potential as they are naturally tissue resident and hence primed for this environment. In addition, their ability to recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than one specific antigen presented by the MHC provides an additional advantage for both specificity of response and maintenance of efficacy.

T cells act as orchestrators of an immune response and, following recognition of a cell as malignant, they induce maturation of monocytes and signal to alpha beta T cells, hence increasing immunogenicity of the tumor and providing a sustained response, with potential even in tumors with low mutational load which have proven challenging with other immunotherapies.

MC: The new spin-out company, Adaptate Biotherapeutics, will build on GammaDelta's knowledge to modulate T-cell activity using therapeutic antibodies. Why have you decided to create a spin-out focusing on this area of research?NM: GammaDelta Therapeutics was formed in 2016 to harness the unique properties of T cells, and since then has gained extensive knowledge of T-cell biology. In addition to gaining insight into cell growth and isolation, the companys scientists have also discovered a number of targets and antibodies that have potential to modulate the activity of T-cells in situ.

GammaDelta Therapeutics now has a pipeline of cell therapy products progressing into clinical development under the guidance of CEO, Dr Paolo Paoletti.

Adaptate Biotherapeutics will be developing antibodies which will be administered to cancer patients to modulate activity of the patient's gamma delta T cells in situ.

Delivery of cell therapy and antibody therapeutics each needs focus and specific skillsets and formation of two independent entities will facilitate this. The two companies share a common goal to harness the potential of T cells to bring effective therapies to patients. Both benefit from support of the scientific founding team and have common investors, Abingworth and Takeda Pharmaceuticals.MC; Your goal is to develop targets and antibodies that can modulate the activity of T-cells and advance them into clinical studies. What challenges exist here, and how do you hope to overcome them?

Our assets at Adaptate Biotherapeutics are currently at the pre-clinical stage and therefore face the non-clinical development risks for a novel therapy. However, these risks are mitigated by biology understanding from our scientific founders and the work at GammaDelta Therapeutics to date.

One of our challenges is in selecting the most suitable patient population for initial trials. There is potential for opportunity for our therapeutics in multiple indications but the utility of animal models in modelling the human immune compartment and human tumor setting is limited. Therefore in vitro and ex vivo models are important, in addition to the learnings from other clinical studies.

MC: GammaDelta Therapeutics formed in 2016 to gain extensive knowledge of T-cell biology and to developing a portfolio of investigational cell therapies. Some of these cell therapies are poised to enter clinical development. Can you tell us any further information about these therapies?NM: GammaDelta was set up to develop cell-based therapy utilizing ex-vivo expanded tissue resident gd T cells. Subsequent acquisition of Lymphact SAS allowed GammaDelta to augment its capabilities with a platform for ex-vivo expansion of blood derived V1 cells. GammaDelta is focussed on progressing ex-vivo expanded skin and blood derived V1 cells to the clinic both in unengineered and engineered formats. Clinical trials are currently on track to commence in the next 12-18 months.

MC: Your press release states: "The two companies will continue sharing their insights into T-cell biology as they work towards developing different therapeutic modalities". How will you continue to share insights here?NM: Antibodies and cells represent complementary approaches to realizing the potential of T cell activity for patients with solid and haematological malignancies.

The two companies will work together in areas of common interest in the biology of these fascinating cells, such as understanding the phenotype and behavior of T cells in tumors and mechanisms of cell regulation as well as the effects of antibody on the T cells.

We have deliberately established a contractual framework that allows efficient collaboration between scientists of both the companies via formal and informal meetings.

MC: What are your hopes for the future of Adaptate Biotherapeutics?NM: This is a remarkable time in the development of new immune therapies, and the role of "non-conventional" cell types of the immune system is coming to the fore as we recognize the successes achieved to date and the needs of patients and related scientific challenges that remain.

Both GammaDelta Therapeutics and Adaptate Biotherapeutics are at the lead of translating our increasing understanding of T cell biology and its potential into therapies to address these unmet needs.

Adaptate Biotherapeutics has a fantastic opportunity to build and accelerate a portfolio of antibody-based approaches in this novel area and I look forward to the successful translation of this science into therapies with the support of our investors at Abingworth and Takeda Pharmaceuticals.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics was speaking with Molly Campbell, Science Writer, Technology Networks.

Read more here:
Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks

Bradley J. Fikes, an ever-on-the move ball of energy who roamed the labs of San Diego as the Union-Tribunes biotech writer, chronicling scientists efforts to find ways to alleviate human suffering, died on Wednesday. He was 61.

His family said he passed away of natural causes at his home in Grantville. He had been dividing his time between poring through medical journals and exploring his two other great loves, the San Diego Zoo and Safari Park in Escondido.

Fikes who was part Dr. Dolittle, part Inspector Gadget was especially excited earlier this week as he pulled together a story about two extremely rare platypuses that are being introduced at the zoo.

He talked about it almost non-stop as we drove back and forth between the zoo, said Michelle Guerrero, a Union-Tribune illustrator and graphics reporter. He knew how animals evolve, their relationship with humans, and how they ended up at zoos.

He had the wonderment of a child, the complexity of a scientist and an artful way of coming up with the words to explain it all.

This is the last known photograph of Bradley J. Fikes, the Union-Tribunes biotech writer

(Howard Lipin/The San Diego Union-Tribune)

Fikes was forever in the middle of things, in a literal and figurative sense.

Every Friday, he staked out a table at Bella Vista, a heavily-trafficked cafe between the Salk Institute and UC San Diego. In science, anybody whos anybody and everybody who wants to become somebody hangs out at Bella and networks.

Fikes listened in, took notes, then speed-wrote stories that were devoured by the biotech brigade. Fikes could talk non-stop for 30 minutes about the nature of pluripotent stem cells, then do another half-hour on telomeres and wrap up with some thoughts on chimeras.

He also hung at Bella because of the food. He loved the comfort fare. He loved it so much that Bellas owner, Amanda Caniglia, named a spaghetti dish after him. She called it Il Journalista.

Fikes was impossible to miss. By his own admission, he was a walking fashion disaster. He wore odd-colored business shirts that clashed with his suspenders, and slacks that never made contact with an iron. At times, cellphone cables hung out of his pockets like limp licorice. He feared not having enough power to use his cellphone to watch Black Sabbath and Van Halen videos on YouTube.

People lovingly teased him, hoping for a retort. He often snapped his own suspenders, smiled, and asked, Are you jealous?

News of his death elicited a wave of sorrow and praise Thursday from the countys science industry, whose denizens knew Fikes as a deliciously quirky figure who understood the arcane language of science and the people who are drawn to it.

I always prepped scientists who were meeting him for the first time not to be fooled by the red suspenders and taped glasses, said Chris Emery, communications director at Scripps Research in La Jolla. Bradley is the most legit science reporter youll encounter.

Fikes also was lauded for highlighting the needs and interests of patients, particularly Theresa Blanda and Nancy Davidson, a pair of Orange County women who suffered from debilitating blood cancers.

He followed their cases closely as they sought experimental drugs that might keep them alive. Blanda also supported the biotech companies who were willing to pursue fresh alternatives, even though the outlook was grim.

Blanda later died. But UC San Diego cancer specialist Catriona Jamieson, who helped with the womens treatment, said Fikes was invaluable in telling their stories.

Bradley championed their cause by telling their stories clearly, said Jamieson. He was a serious advocate for patients. He persevered and got difficult stories right. Ive always been a big fan of Bradley.

He was also very keen on gender diversity in life science, said Dawn Barry, president and co-founder of LunaDNA. We lost such a warm, engaged, important San Diego citizen.

Bradley Joseph Fikes was born in San Diego on Jan. 30, 1958, the son of Garland Fikes, a blueprinter, and Trudy Fikes, a nurse who worked at Mercy Hospital.

He learned to read and comprehend difficult information early, which led to a life-shaping moment when he was roughly 6 years old.

Fikes discovered a medical encyclopedia that captivated his attention. One afternoon, he shared the book with neighborhood children, which alarmed their parents because it showed explicit images of the human body.

It was just anatomy; there was nothing wrong with it, said Vanessa Dimalanta, one of Fikes three sisters. That was Brad. Always reading, always sharing with others.

His obsession with science deepened while he was attending San Diego High School and it grew at San Diego State University, where he found his calling journalism.

Like hundreds before him, Fikes joined the Daily Aztec, the campus newspaper, which operated in a raucous newsroom that had male mannequin legs hanging from the ceiling.

This is where he found his tribe, said Karla Peterson, a Union-Tribune columnist who also was part of the Aztec staff.

He loved the work and was at it all of the time. He had so much energy. When we threw parties, Bradley was always the first to arrive and the last to leave. He was happy. He knew how to enjoy life.

Union-Tribune theater critic James Hebert said, He struck me as a total original from the moment I met him like our own slightly mellower answer to Hunter S. Thompson. And it was always resoundingly clear just from being around him that he loved what he did.

After graduating from San Diego State in 1984, Fikes worked as a freelance writer and then spent three years as a staff writer for the Chula Vista Star-News. In 1990, he joined the staff of the San Diego Business Journal, where he worked for six years. Then he spent another year covering business for the San Diego Daily Transcript.

Because of the deep connections he had built in the local business community, Fikes took a brief career detour into corporate communications for a high-tech firm in 1997. He quickly realized his mistake. Despite the higher salary, Fikes missed working as a newspaper journalist. In 1997, he contacted then-North County Times business editor Pam Kragen looking for a staff-writing job. He was hired immediately.

Brad had a bit of the nutty professor about him when it came to style, but his brain worked like a computer, Kragen said.

He was able to store vast amounts of information and call on it to write knowledgeably, accurately, quickly and prolifically. After returning to the newspaper business, I remember Brad telling me that all he ever really wanted to do was to be a journalist because he loved the process of discovering something new and then sharing it with readers. He was very proud to work at the Union-Tribune.

He loved the job and the newsroom was his home.

Union-Tribune Publisher and Editor Jeff Light said, Bradley had a rare combination of intellect, curiosity and character. It made him a wonderful journalist.

By character, I mean the strength to be true to himself. But he also had a vulnerability that made you feel protective of him. He was a beloved figure. Our newsroom will miss him terribly.

Fikes is survived by three sisters, Sue Tate of San Diego; Vanessa Dimalanta of San Diego, and Kimberley Cross of San Diego.

Originally posted here:
Union-Tribune biotech writer Bradley J. Fikes, beloved by colleagues, dies at 61 - The San Diego Union-Tribune

Eileen Booker sat in her Southern California home last Sunday night, watching the Packers game like she does every week.

She grew up in Green Bay, and her sister still lives there. Her parents bought season tickets in 1957 and her father never missed a home game. She remembers sticking to frigid metal bleachers as a kid until the clock showed zeroes in the fourth quarter, win or lose, and always burning her lips with hot chocolate.

Still a die-hard fan today, Eileen was glued to her television for a prime-time game between the Packers and 49ers, even as her favorite team trailed, 10-0, early in the second quarter.

She had no idea her name was about to be plastered on TV screens across America.

After Packers outside linebacker ZaDarius Smith sacked 49ers quarterback Jimmy Garoppolo deep in 49ers territory, he immediately found the nearest camera and lifted his jersey, revealing a white undershirt that read, WE ...

Originally posted here:
How the Packers' Za'Darius Smith brought joy and awareness to one woman's cancer fight - The Athletic

Stem Cell Banking Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Stem Cell Banking industry overview and then goes into each and every detail.

Stem Cell Banking Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Stem Cell Banking also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

High potential of cord blood and tissues for the treatment of patients with autoimmune diseases is expected to propel the market growth. Moreover, currently available immunosuppressive agents such as steroids, induce long term side effects despite temporary improvements. According to the Health Research Funding, 2015, around 28% of cord blood transplants have been used to treat genetic diseases, with the most common genetic disease treated being severe combined immune deficiency, followed by aplastic anemia. According to the National Cord Blood Program, 2015, cord blood from unrelated donors has been used as an alternative to bone marrow or mobilized stem cells, as a source of hematopoietic stem cells, with over 35,000 stem cell transplants successfully performed worldwide.

Stem Cell Banking Market competition by top manufacturers/players, with Stem Cell Banking sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/1354

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1354

Stem Cell Banking Market Dynamics in the world mainly, the worldwide 2018-2026 Stem Cell Banking Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Stem Cell Banking market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Stem Cell Banking industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/1354

In this study, the years considered to estimate the market size of 2018-2026 Stem Cell Banking Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

The rest is here:
Stem Cell Banking Market to Expand Steadily in the Coming Years till 2018-2026 - Crypto Journal

The latest research report on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Ricerca Alfa, presents a detailed analysis concerning market share, market valuations, revenue estimation, SWOT analysis, and regional spectrum of the business. The report further highlights key challenges and growth prospects of the market, while examining the business outlook comprising expansion strategies implemented by market leaders.

The Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Request for Sample of this [emailprotected] https://www.ricercaalfa.com/page/request-sample/50850/Global-Circulating-Tumor-Cells-CTCs-and-Cancer-Stem-Cells-CSCs-Market

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.

Methodology used in this report:

Our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. The research process begins with extensive data mining, using authentic sources such as trade magazines, technical publications, independent studies along with paid avenues such as ICIS, Hoovers, etc. Primary objectives of data mining include:

All the above factors are identified and analyzed in detail, with their present and expected market impact, which is quantified and used to derive market growth expectation. Market forecast is built using statistical analysis with models built around time-variance, regression and correlation analytics.

Market segment by Type, the product can be split into

CellSearch, Other, Type III,

Market segment by Application, split into

Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatment,

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request for this Report: https://www.ricercaalfa.com/publishersDetails/50850/global-1245-tetramethylbenzene-durene-market-research-report-2019-by-m.html

Questions that the report answers with regards to the competitive hierarchy of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market:

An overview of the regional spectrum:

Table of Content

1 Introduction Of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Deployment Model5.1 Overview

6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Solution6.1 Overview

7 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Vertical7.1 Overview

8 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Enquiry Before Buying: https://www.ricercaalfa.com/page/enquire/50850/Global-Circulating-Tumor-Cells-CTCs-and-Cancer-Stem-Cells-CSCs-Market

About Us:

Ricerca Alfa is one of the top market research, consulting, and report resellers in the business world, dedicated to assist worldwide organizations to deliver practical and lasting results through valuable recommendations about emerging technology and industry trends, granular quantitative as well as qualitative information. We have comprehensive database of market research reports that are backed by the prominent research analysts seeking reliable facts and unbiased market insights.

Contact Us:

https://www.ricercaalfa.com/

Ricerca Alfa

Galaxy One, Besides EON IT Park, EON Free Zone, Kharadi, Pune, Maharashtra, India 411014

+91 90213 50030 (India)

+1 619-663-3211 (U.S)

[emailprotected]

Continued here:
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Advanced Technologies & Growth Opportunities in Global Industry By 2025 -...

A new professional intelligence report published by Stats and Reports with titleGlobal Cancer Stem Cell Market Report 2025has the ability to help the decision makers in the most important market in the world that has played a significant important role in making a progressive impact on the global economy. The Global Cancer Stem Cell Market Report presents and showcases a vigorous vision of the global scenario in terms of market size, market potentials and competitive environment. The study is derived from primary and secondary statistical data and consists of qualitative and quantitative analysis of industry and key players. For the purpose of this study, the report includes major players such asThermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics, Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., OncoMed Pharmaceuticals, Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME, Inc..

Sample Report & Graphs & Charts @:https://www.statsandreports.com/request-sample/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Industry Overview of Global Cancer Stem Cell:To engage or target the Global Cancer Stem Cell Market, this study will provide a comprehensive view. It is important to keep Market knowledge up to date with Applications Stem Cell Based Cancer Therapy, Targeted CSCs, Product types Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others. If you have other players / manufacturers in your geography, or if you need regional or country-specific report, we can provide customizations based on your requirements.

This research will help you understand the markets or regions or countries that you need to focus on for years to channel efforts and investments to maximize growth and profitability. The report presents an in-depth analysis of key vendors or key players in the Market competitive landscape and Market.

Check Discount @https://www.statsandreports.com/request-sample/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

** We will also include opportunities to utilize in micro Markets that stakeholders can invest in, detailed analysis of key competitors and key services.

Furthermore, the years considered for the study are as follows:Historical year 2014-2018Base year 2019Forecast period** 2019 to 2025[** unless otherwise stated]

Sub-section of the Market are Listed below:

Product Types of Cancer Stem Cell Market:Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others.

Key Applications/end-users of Global Cancer Stem Cell Market:Stem Cell Based Cancer Therapy, Targeted CSCs.

Major Companies in the Market are:Thermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics, Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., OncoMed Pharmaceuticals, Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME, Inc..

Global Cancer Stem Cell Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Key features and key features of the report are as follows.

Cancer Stem Cell Market overview Changing Market dynamics of industry In-depth Market segmentation by type and application Historical, current and planned Market size in terms of quantity and value Recent industry trends and developments Cancer Stem Cell Competitive landscape of the Market Major player and product delivery strategy Potential growth potential and niche Market / region Cancer Stem Cell neutral view on Market performance Market holders must have the information to maintain and strengthen their Market share.

Read Full TOC of Research Study at @https://www.statsandreports.com/report/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Key Highlights of TOC:

Chapter 1: Global Cancer Stem Cell Market Industry Overview1.1 Cancer Stem Cell Industry1.1.1 Overview Major Enterprise Products1.2 Cancer Stem Cell Market Segment1.2.1 Corporate chain1.2.2 Consumer Distribution1.3 Pricing and Cost Overview

Chapter Two: Global Cancer Stem Cell Market Demand2.1 Segment Overview2.1.1 APPLICATION 12.1.2 APPLICATION 22.1.3 Other2.2 Global Cancer Stem Cell Market Size by Demand2.3 Global Cancer Stem Cell Market Forecast by Demand

Chapter Three: Global Cancer Stem Cell Market by Type3.1 By Type3.1.1 TYPE 13.1.2 TYPE 23.2 Cancer Stem Cell Market Size by Type3.3 Cancer Stem Cell Market Forecast by Type

Chapter Four: Major Region of Cancer Stem Cell Market4.1 Global Cancer Stem Cell Sales4.2 Global Cancer Stem Cell Revenue & Market share

..

Buy this Report:https://www.statsandreports.com/placeorder?report=294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Key questions answered Who are the main competitors in the market and what are the key business plans? What are the key concerns of the five forces analysis of the Global Cancer Stem Cell Market? What are different prospects and threats faced by the dealers in the Global Cancer Stem Cell Market? What are the strengths and weaknesses of the key vendors?

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact:Stats and ReportsSatish K. (Global Sales Manager)Mangalam Chamber, Office No 16, Paud RoadSankalp Society, Kothrud, Pune, Maharashtra 411038Phone: +1 650-646-3808Email:sales@statsandreports.comWeb:https://www.statsandreports.comFollow Us on:LinkedIN|Twitter|

See the article here:
Cancer Stem Cell Market Analysis Focusing on Top Key Players Thermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline...

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

GREENVILLE, S.C.Hailie and Treylin Hyman saw the bruising on their baby girls leg as a sign that the active 1-year-old was learning to walk.

But as a blood test would later reveal, little Maci was actually suffering from an extremely rare blood cancer that threatened her life without a risky treatment - atreatmentalmost as dangerous as the disease.

In the beginning, it was very scary, Hailie Hyman told The Greenville News.

I couldnt think of anything but the bad things, she confessed. It was all about the statistics. And the statistics arent good.

Terrifying months followed the diagnosis, punctuated by one critical complication after another, leaving the Boiling Springs couple to wonder if Maci would survive.

Somehow, though, the blue-eyed toddler pulled through.And now her family is looking forward to a special Thanksgiving with much to be grateful for.

Alyssa Carson is 18 and has a pilot's license: She wants to be in the crew that colonizes Mars

The Hymans journey began last February atMacis 1-year-old well-child checkup.

We had no idea anything was wrong, her mom said.But they did a routine (blood test) and a couple of hours later, we got a call saying her platelets were very low.

The Hymans were referred to a hematologist who found other abnormalities in Macis blood and scheduled a bone marrow biopsy to investigate further.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

During the procedure, the child suffered an aneurysm in an artery and went into cardiac arrest. The team performed CPR on her for 20 minutes before she was stabilized, her mom said.

Later, in the pediatric intensive care unit, she suffered internal bleeding, too.

It was really hard, she said. There were many nights that I would just pray and pray and pray.

Initially believing Maci had leukemia, doctors subsequently determined she had myelodysplastic syndrome, or MDS.

The condition occurs when abnormal cells in the bone marrow leave the patient unable to make enough blood, according to the American Cancer Society.

Its rare, afflicting as few 10,000 Americans a year, though the actual number is unknown.

Maci Hyman, 1, interacts with hospital staff before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

In children, its rarer still. Most people arediagnosed in their 70s.

We were told that just four out of 1 million children get it every year, Hailie Hyman said.

That made the diagnosis elusive at first, said Dr. Nichole Bryant, a pediatric hematologist-oncologist with Prisma Health-Upstate, formerly Greenville Health System.

Shes the only one Ive seen in my career, she said.

Maci had to have regular blood transfusions, antibiotics and other medications to fight the MDS, Bryant said. But the only hope for a cure was a stem cell transplant at the Medical University of South Carolina in Charleston.

When they said that was the only treatment plan for MDS, I of course went to Google, Hailie Hyman said. I read about transplant patients and ...all the complications. It was terrifying. But no matter how many bad things I saw, we had to do it. There is no other option.

The transplantis extremely risky.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

First, high doses of chemotherapy are given to destroy the diseased bone marrow, leaving the patient without an immune system, so fighting infections becomes a challenge. Then healthy donor marrow is infused.

Its also fraught with potentially life-threatening complications, including graft vs. host disease, which occurs when immune cells from the donor attack the patients body, Bryant said. Other complications include permanent kidney damage and gastrointestinal problems.

They have to go to hell and back, she said. But its the only option for long-term survival.

Maci had a really rough start, suffering lots and lots and lots of complications, Bryant said.

Her kidneys failed, so she wound up on dialysis. When she couldnt breathe on her own, she was put on a ventilator. And because she couldnt eat, she had to be tube fed.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

She had blistering sores in her mouth and throughout her GI tract, her mom said. Because her liver wasnt functioning properly, her abdomen filled up with fluid that had to be drained. She was bleeding so profusely in her lungs that one of them collapsed.

Maci, who was sedated through much of it, was put on full life support, she said.

That night we almost lost her, her mom said. We were in the hallway crying our eyes out. We didnt know what do to or think. It was pretty scary for a while.

Somehow, Maci made it.

There were so many times during her first months that it seemed like she would not survive, Bryant said. So the fact that she is here ... is really a miracle.

Macis family found an unrelated donor through the National Marrow Donor Program, enlisting hundreds of other people to join the registry in the process, Bryant said.

Nichole Bryant, M.D.(Photo: Provided)

It was an important part of their journey that maybe didnt directly benefit Maci, she said. But if everybody did that, we wouldnt have difficulty finding a donor for anybody.

Doctors have no explanation for why Maci got MDS. She didnt carry the genetic mutation for it and there is no family history.

She is a rare child - and not in a good way, her mom said, adding,Youve got to laugh sometimes or youre going to cry.

A dying man wanted one last beer with his sons: The moment resonated with thousands

Maci was admitted to MUSC on June 2 and released on Oct. 14.

The Hymans, both 22, spent the entire time in Charlestonwhile Hailies mom cared for their older daughter, Athena, now 2.

Treylins employer held his welding job open for him. And other friends and family members did what they could to help.

We had many, many people very generously donate to us to cover expenses at home and living expenses where we were, Hailie Hyman said.

We are thankful for everyone who helped us through it the cards, the gifts, the donations. Every single cent is greatly appreciated.

Maci's doing well, but recovery from a transplant can take months to years, Bryant said.

Her kidneys are functioning again so she was able to come off dialysis. But she still must take many medications, including anti-rejection drugs that suppress her immune system and leaveher at risk for infection. And she still must be tube fed.

She is miles ahead of where she was two months ago, Bryant said. But she still has a long way to go. Its a long, long road.

Macis mom says she can be up and playing one day and flopped over on the couch another. She still experiences a lot of nausea and vomiting, but is doing well compared to where she was.

Hailie Hyman pulls her daughter Maci, 1, in a wagon in the hallway before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

So as the nation pauses to give thanks this Thanksgiving, she says the family will be countingtheir many blessings family andfriends, Gods mercy, andthe doctors and nurses who saved Macis life.

She has battled a lot and overcome a lot, she said. I have no doubt she will be able to get through.

Want to know more about becoming a marrow donor? Go to bethematch.org.

Follow Liv Osby on Twitter:@livgnews

104-year-old woman bags first buck: 'Never underestimate the power of our senior citizens'

Indiana hospital sued: More than 1,000 patients potentially exposed to HIV or hepatitis

Read or Share this story: https://www.usatoday.com/story/news/health/2019/11/28/south-carolina-toddler-survives-rare-blood-cancer-risky-procedure/4321002002/

Read the original:
South Carolina toddler survives rare cancer and the risky procedure used to treat it - USA TODAY

Lynne D. Neumayr, MD; Carolyn C. Hoppe, MD, MPH; Clark Brown, MD, PhD

2 decades; in 2017, L-glutamine oral powder was approved for the prevention of the acute complications of SCD. During the last several years there has been a dramatic increase in research into treatments that address distinct elements of SCD pathophysiology and even new curative approaches that provide new hope to patients and physicians for a clinically consequential disease that has long been neglected.

Am J Manag Care. 2019;25:-S0

For author information and disclosures, see end of text.

Background

Sickle cell disease (SCD) is a common, severe disorder that includes congenital hemolytic anemias caused by inherited point mutations in the -globin gene.1 These mutations result in abnormal hemoglobin polymerization, which leads to a cascade of physiologic consequences, including erythrocyte rigidity, vaso-occlusion, chronic anemia, hemolysis, and vasculopathy.1 This change in the behavior of hemoglobin has profound clinical consequences, including recurrent pain episodes (known as sickle cellrelated pain crises or vaso-occlusive crises), hemolytic anemia, multiorgan dysfunction, and premature death.1 Newborn screening, early immunization, and prophylactic penicillin treatment in infants and children, as well as comprehensive management for pain and disease complications, have improved outcomes in these patients; however, the average life expectancy of a patient with SCD remains only about 40 to 50 years.2,3

Globally, it is expected that approximately 306,000 people are born every year with SCD; an estimated 79% of these births occur in sub-Saharan Africa. In the United States, approximately 100,000 people are living with SCD, including approximately 1 in 365 African Americans and 1 in 16,300 Hispanic Americans.4,5

The impact of SCD on patient quality of life (QOL) has been estimated to be greater than that of cystic fibrosis and similar to that of patients undergoing hemodialysis, which is widely recognized as having a severe impact on QOL.6 Impairments are seen across functional and QOL domains and are particularly profound in terms of pain, fatigue, and physical function.7,8

Management of SCD can be intensive, time-consuming, and costly, particularly in patients with recurrent acute pain episodes. On average, patients with SCD experience approximately 3 vaso-occlusive crises each year, of which at least 1 requires inpatient treatment and 1 requires emergency department management without admission.9 Among patients who require admission, the median length of stay is approximately 6 days.9 More than 90% of acute hospital admissions for patients with SCD are due to severe and unpredictable pain crises, and these crises are responsible for 85% of all acute medical care for these patients.10 Estimates of the lifetime care costs for SCD vary dramatically based on underlying assumptions, from approximately $500,000 to nearly $9 million.11,12

Few options are currently available for the management of SCD. Hydroxyurea, which until recently was the only FDA-approved drug for adults with severe SCD genotypes (and is also used off-label for adults with less severe genotypes and children ages 9 months to 2 years), improves the course of SCD and results in substantial cost savings.13,14 Unfortunately, hydroxyurea is underutilized and treatment adherence is poor for a variety of reasons.15 Recently, L-glutamine became the second drug approved for SCD in the United States.16

Red blood cell (RBC) transfusion is common in patients with SCD for the management of acute complications, and regular or chronic transfusion regimens are used for stroke prevention in at-risk patients. Despite being effective for the management of both acute and chronic complications of SCD,1 transfusion is associated with annual costs exceeding $60,000; it requires routine, costly iron chelation therapy to prevent liver and other organ damage as a result of iron overload; and it is associated with the risk of alloimmunization.12,17 Stem cell transplantation, while potentially curative, is limited by a scarcity of matched donors and the risks for adverse events (AEs) and death.18 Currently under investigation are novel gene therapies that offer considerable hope for a more broadly applicable curative therapy.

This review will first examine our current understanding of the pathogenesis of SCD and explore the broad range of clinical manifestations of this disease. It will then focus on the relatively limited current therapeutic options, recent clinical trials, and near-term therapies for the chronic and acute management of the disease.

The Pathogenesis of SCD

SCD is not a single disorder. Rather, it is a clinical entity that includes a number of heritable hemolytic anemias with widely variable clinical severity and life expectancy. All involve point mutations in the -globin gene, resulting in an abnormal hemoglobin referred to as hemoglobin S (HbS).19 In the most common forms of SCD, which are also the most severe, the patient inherits the sickling gene from both parents and produces HbS exclusively.19 The compound heterozygous forms of SCD are defined by the production of HbS and another abnormal -globin protein.19

The point mutation in the -globin gene results in the substitution of glutamic acid in position 6 with valine in the resulting protein.1 This small change in the amino acid sequence of hemoglobin has profound structural and functional consequences, because under low oxygen conditions, it produces a hydrophobic region in deoxygenated HbS that promotes binding between the 1 and 2 chains of 2 hemoglobin molecules, ultimately resulting in HbS polymerization into rod-shaped structures.

The polymerization of HbS changes both the shape and physical properties of RBCs, resulting in red cell dehydration, increased rigidity, and a variety of deleterious structural abnormalities, including the characteristic sickled RBCs from which the disease gets its name.20 The rigidity of deoxygenated RBCs contributes to vaso-occlusion by impeding their passage through the microcirculation.1 Repeated cycles of tissue hypoxia and reperfusion damage elicits upregulation of adhesion molecules, such as P-selectin and E-selectin, on the vascular endothelium. This promotes adherence of RBCs, white blood cells (WBCs), and platelets, further contributing to a propensity for vaso-occlusive events and a chronic inflammatory state.1,20,21

Hemolytic anemia is an important driver of the pathophysiology of SCD. The average RBC in homozygous SCD survives only approximately 10 to 20 days, compared with 120 days for normal RBCs.22 Destruction and release of the contents of RBCs into the circulation results in progressive endothelial dysfunction and proliferation, which may in part be due to scavenging of nitric oxide (a key regulator of vascular tone) by extracellular hemoglobin.20,23-25 The end result is an impaired vasodilatory response, chronic activation of endothelial cells and platelets, and an ongoing inflammatory state. Exposure of phosphatidylserine, which is normally only found on the inner surface of the RBC membrane, also occurs, and this predisposes cells to premature lysis and promotes the activation of coagulation pathways.26,27 Excess levels of adenosine, often related to stress, are also seen in SCD. Adenosine signaling contributes to the pathophysiology of SCD by stimulating the production of erythrocyte 2,3-bisphosphoglycerate, an intracellular signal that decreases oxygen binding to hemoglobin.28

Clinical Consequences of SCD

SCD is associated with a broad range of acute and chronic complications that have a profound impact on patients, their families, and society. As noted previously, patients with SCD can present with a broad range of manifestations and disease severities depending upon the underlying genetics of their disease; the discussion below primarily refers to the most common homozygous form of the disease.

Acute pain events affect approximately 60% of patients with SCD in any given year.29-31 Such events can begin as early as 6 months of age and may recur throughout the patients life. Acute pain events are responsible for more than three-quarters of hospitalizations in patients with SCD,32 and from the perspective of the patient, they are often considered the most important and disabling consequence of the disease.32,33 Many such events can be managed at home with oral analgesics, hydration, and rest; however, in some cases, patients must be administered opioids in the emergency department or hospital setting to achieve adequate pain control.34 Acute pain events are major contributors to the high healthcare utilization of many patients with SCD.32

Stroke is the most common, and most concerning, long-term risk of homozygous SCD. The risk for stroke in children with SCD is approximately 300 times higher than for children without SCD, and approximately 25% of adults with SCA will have a stroke.20,35 Silent cerebral infarcts occur in 27% of patients by age 6 years and in 37% by age 14 years; the prevalence of silent cerebral infarct in adults is less well defined, although it is likely that progressive injury occurs as patients age.36 Cognitive impairment is seen in 5 to 9 times as many patients with SCD as compared with patients without SCD, likely due to silent repetitive ischemic brain injury.29 The use of transcranial Doppler or MRI to screen patients can help to identify patients who would benefit from additional measures to decrease the frequency and severity of stroke.20

Continued here:
Sickle Cell Disease: Current Treatment and Emerging Therapies - AJMC.com Managed Markets Network